Trial Profile
A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Carbidopa; Entacapone; Levodopa
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors NeuroDerm
- 04 Dec 2019 Status changed from recruiting to completed.
- 08 Jun 2017 Pooled (n=46) results of NCT02096601 and NCT01883505 trials assessing levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 28 Apr 2017 Results assessing levodopa pharmacokinetic profile after continuous subcutaneous administration of ND0612, presented at the 69th Annual Meeting of the American Academy of Neurology